数据
资源
版本对比
免费注册
预约演示
免费注册
ThromboGenics Ltd.
and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant
TB-402
2007-09-07
·
BioSpace
合作
抗体
创新药
LEUVEN, Belgium and LUND, Sweden, September 7 /PRNewswire/ -- - Decision Taken to Advance Novel, Long-Acting Anticoagulant Into Phase II Clinical Development ThromboGenics NV , a biotechnology company focused on
vascular disease
, and co-development partner,
BioInvent International
(Nordic Exchange: BINV), announce today that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of
TB-402
, which is being developed for the prevention of
venous thromboembolic disorders
(VTE - blood clots).
TB-402
is a recombinant human monoclonal antibody that targets factor VIII, a component of the coagulation cascade. This antibody is a promising novel anticoagulant agent particularly because it only partially inhibits factor VIII activity even when administrated in very high doses. This may potentially decrease the risk of undesirable bleedings and the need for monitoring, which are the main concerns associated with anticoagulants currently on the market. The trial, performed in Denmark, was a randomized, single-dose, placebo-controlled, dose-escalation trial in healthy male volunteers. 56 volunteers were enrolled into the trial, including both younger age volunteers (18-45) and older age volunteers (55-76). Preliminary results of the trial showed that
TB-402
met both the primary (safety and tolerability) and secondary (pharmacokinetic and pharmacodynamic) endpoints. The drug was well tolerated and the study showed that
TB-402
's prolonged half-life will allow for single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term
stroke
prevention in
atrial fibrillation (AF)
, as opposed to daily treatment with current anticoagulants. Importantly, the findings confirm that
TB-402
achieves only partial inhibition of factor VIII activity without the undesired effect of total factor VIII inactivation. Final data analysis of the first Phase I trial will be available later this year. Based on these results, and after a review of preliminary results with the Scientific Advisory Board for this program, the Joint Steering Committee of ThromboGenics and BioInvent has decided to move
TB-402
into Phase II clinical development. As part of the development programme, drug interaction studies will be performed in parallel with the preparation for Phase II, which is expected to start in H1 2008. The initial Phase II trial will be a dose-ranging clinical trial evaluating safety and efficacy (ability to prevent
deep vein thrombosis - DVT
) in an orthopaedic surgery setting. Prof. Desire Collen, CEO of
ThromboGenics
, commenting on today's announcement, said: "We and our co-development partner, BioInvent, are extremely pleased to have completed the first
TB-402
Phase I trial. Initial results of the trial are very encouraging and show that
TB-402
is safe and has the potential to fill a significant unmet need in multiple major indications by allowing for single or once-monthly administration to prevent and treat debilitating and life-threatening conditions, such as
deep vein thrombosis
and
stroke
secondary to
atrial fibrillation
. We are looking forward to moving
TB-402
into Phase II clinical trials in the first half of 2008." Svein Mathisen, CEO of BioInvent, added, "We are very satisfied that the trial has demonstrated that
TB-402
is safe, and that it inhibits Factor VIII as predicted. The decision to advance into Phase II clinical development is once again evidence that our partnership is successful, proving the synergy of
ThromboGenics
' knowledge within vascular medicine and BioInvent's skills in antibody development."
Thromboembolic Disease
Thromboembolic diseases
represent a major unmet medical need. The annual sales of anticoagulants (drugs that prevent blood clots) worldwide are over $5 billion. Nevertheless, available anticoagulants are still inconvenient and associated with a high risk of
bleeding
. Improved anticoagulants are therefore required. In particular, agents that allow for improved ease of administration (without requirement for daily dosing and frequent dose adjustment) would fill a significant unmet need. Prevention and Treatment of
Venous Thromboembolic disease (VTE)
Venous thromboembolic disease
(
deep vein thrombosis (DVT)
,
pulmonary embolism
) represents a major health issue, with an incidence of 1 to 3 per 1000 individuals per year and a high early mortality rate. One of the risk factors for VTE is major orthopaedic surgery. Anticoagulation prophylaxis is therefore indicated in this setting. In addition, in patients who develop a VTE, anticoagulation treatment for at least 6 months is indicated. Therefore, an agent allowing for once-a-month treatment in an outpatient setting is foreseen as an important option for the treatment of VTE.
Stroke
Prevention in
Atrial Fibrillation (AF)
Atrial fibrillation (AF)
, which is a strong risk factor for
ischemic stroke
, is the most common sustained arrhythmia observed in clinical practice. The prevalence of
AF
is estimated at 0.4% of the general population and increases with age, rising to 8.8% in the group aged 80-89 years. Given the aging population in the U.S. and other developed countries, the overall prevalence of
AF
is expected to continue to grow over the next several decades. About
ThromboGenics
ThromboGenics
is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of
vascular diseases
. The Company has several programs in Phase II clinical development including
microplasmin
, which is being evaluated as a treatment for
vitreoretinal disorders
and as a thrombolytic agent for
vascular occlusive diseases
, including
acute stroke
.
ThromboGenics
also has
TB-402
in Phase I clinical development and
TB-403
scheduled to enter clinical development at the end of 2007, plus several other drug candidates in preclinical development with preclinical proof-of-principle demonstrated. The Company has built strong links with the
University of Leuven
and has exclusive rights to certain therapeutics developed at the
University
. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Ireland and the U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at . About BioInvent
BioInvent International AB
, listed on The Nordic
Exchange
(OMXS:BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of
thrombosis
,
cancer
,
atherosclerosis
and
ophthalmic diseases
. In January 2007, the Company announced a major strategic alliance with American-based
Genentech, Inc.
in the cardiovascular field. These projects are based on a competitive and in substance patented technology platform. The scope and strength of this platform is also utilised by partners, such as
ALK-Abello
,
ImmunoGen
, OrbusNeich,
Sanofi-Aventis
,
Syngenta
, UCB and
XOMA.
The Company, which currently has 96 employees, is located at Ideon in Lund. More information is available at . Important information about forward-looking statements Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus. ThromboGenics NV CONTACT: For further information please contact:
ThromboGenics
, ProfDésiré Collen, CEO, Tel: +32-(0)-16-34-61-94;
BioInvent
, SveinMathisen, CEO, Tel: +46-(0)-46-286-85-67, Mobile: +46-(0)-708-97-82-13;Cristina Glad, Executive Vice President, Tel: +46-(0)-46-286-85-51, Mobile:+46-(0)-708-16-85-70; Citigate Dewe Rogerson, David Dible / ValerieAuffray, Tel: +44-(0)-207-638-95-71; Northbank Communications, Katja Stout,Director, Tel: +44-(0)-20-7268-3002
机构
Thrombogenics, Inc.
Katholieke Universiteit Leuven
Ion Exchange (India) Ltd.
[+8]
适应症
血管疾病
静脉血栓栓塞
脑卒中
[+11]
靶点
-
药物
TB-402
奥克纤溶酶
THR-317
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务